




FIG. 1

Binding of anti - Factor Bb mAbs

Clone	Binding to Factor Bb (EC ₅₀ , M)
M4	8.735e-010
M10	3.345e-010
M12	7.612e-010
M17	3.140e-009
M18	3.360e-010
M20	5.461e-010

FIG. 2




FIG. 3

Specificity of Binding to Factor B versus Factor Bb

Anti -Factor Bb Clone	Ratio OD fBb/fB (ELISA)	Binding to Factor B in Solution (SEC)
M4	00.59	+
M10	05.49	-
M12	00.82	+
M17	70.66	-
M18	08.40	-
M20	00.50	+

FIG. 4

Binding of anti - Factor Bb mAbs to Cyno Factor B
and Factor Bb

	Binding Affinity (M)					
	M10	M12	M14	M17	M18	M20
Factor B	3.493E-09	5.563E-09	7.813E-09	Not detected	4.985E-09	2.551E-08
Factor Bb	4.88E-10	2.554E-09	2.503E-09	~ 2.639e-009	4.488E-10	7.163E-08

FIG. 5




FIG. 6




FIG. 7

Inhibition of AP - Mediated C3b Deposition
on Rabbit RBC by anti - Factor Bb Monoclonal
Antibodies




FIG. 8

Inhibition of Complement AP Activity by
anti - Factor Bb Monoclonal Antibodies

Clone	Wieslab AP (IC ₅₀ , M)	AP Hemolysis (IC ₅₀ , M)	C3b Deposition (IC ₅₀ , M)
M4	6.090E-008	1.32E-08	1.4E-08
M10	2.287E-007	3.84E-08	7.78E-08
M12	5.550E-008	1.17E-08	1.22E-08
M17	~ 7.706E-007	4.34E-08	1.2E-07
M18	2.258E-007	3.96E-08	7.68E-08
M20	1.417E-007	3.19E-08	5.41E-08

FIG. 9

Inhibition of Cyno Complement AP Activity by
anti - Factor Bb Monoclonal Antibodies




FIG. 10




FIG. 11

Table 1: Anti-Factor Bb Antibody Sequences

Antibody	CDR-1	CDR-2	CDR-3	V Region
M10 VL	SEQ ID NO: 1 QDVGTA	SEQ ID NO: 2 WAS	SEQ ID NO: 3 HQHSSNPLT	SEQ ID NO: 7 DIVMTQSHKFMSTSVGDRVSITCKA SQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVPDRFTGSGSGTDEFTLI TNVQSEDLAVYFCHQHSSNPLTFGA GTKLELK
M10 VH	SEQ ID NO: 4 GTFFSNYA	SEQ ID NO: 5 ISNRGSYT	SEQ ID NO: 6 ARERPMDY	SEQ ID NO: 8 EVQLVESGGALVKPGGSLKLSCAAS GTFESNYAMSWVRQTPFKRLEWVAT ISNRGSYTYYPDSVKGRTISRDN KNTLYLQMSSLRSEDTALYYCARER PMDYWGQGTSVTVSS

FIG. 12A

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M4 VL	SEQ ID NO: 9	SEQ ID NO: 10	SEQ ID NO: 11	SEQ ID NO: 15
	KSLHSHNGITY	RMS	AQMLERPWT	DIVMTQAAFSNPVTLTGTSASISCS
				SKSLHSHNGITYLYWYLQRPQSPQ
				LLIYRMSNLAGVPDRFSGSGGTD
				FTLRISRVEAEDVGYYCAQMLERP
M4 VH	SEQ ID NO: 12	SEQ ID NO: 13	SEQ ID NO: 14	SEQ ID NO: 16
	GYSFTDYL	INPYNGDA	ARLENDYGFTY	EVQLQQSGPELVKPGASVKMSCKAS
				GYSFTDYLNNWVKQSHGKSLEWIGR
				INPYNGDAFYNQRFKGGKATLTVDKS
				SSTAHEMLRSLTSEDSALYYCARLE
				NDYGFTYWGQGTLLVTVSA

FIG. 12B

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M20 VL	SEQ ID NO: 17	SEQ ID NO: 18	SEQ ID NO: 19	SEQ ID NO: 23
	QGINNY	YTS	QQHSLPWT	THYRASSGINAEYMGDRVITISCSA
				SQGINNYLNWYQQKPDGTVKLLIYY
				TSSLHSGVPSRFSGSGSGTDYSLTI
				SNLEPEDVATYYCQQHSLKPWTFGG
M20 VH	SEQ ID NO: 20	SEQ ID NO: 21	SEQ ID NO: 22	SEQ ID NO: 24
	GFSLSTFGLG	IWNDDK	VQIPYGSRNGFDY	QVTLKESGPGILLQPSQTLSLTCSFS
				GFSLSTFGLGVGWIRQPSGKGLEWL
				ASIWNNDDKYNSDLKRRPTISRDT
				SNSQVFLKISSVDTADTATYFCVQI
				PYGSRNGFDYWGQTSITVSS

FIG. 12C

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M17 VL	SEQ ID NO: 25 QDVGSA	SEQ ID NO: 2 WAS	SEQ ID NO: 26 QQYSSYPYT	SEQ ID NO: 30 DIVMTPSHKEMSTSVGDRVSITCKA
				SQDVGSAAVWYQQKPGHSPKLLIFW
				ASTRHGTGVPDRFTGSGGIDFTLTI
				SNVQSEDLADYFCQQYSSYPYTFGG
				GTRLEIK
M17 VH	SEQ ID NO: 27 GFTFSNFA	SEQ ID NO: 28 ISNGGGYT	SEQ ID NO: 29 ARIYYGSSYEDWFAY	SEQ ID NO: 31 EVQLVESGGVLVKEGGSLKLSCAAS
				GFTFSNFAMSWVRQTPAKRLEWVAT
				ISNGGGYTYYPDSVQGRFTISRDN
				NNTLYLQMSSLRSEDTALYYCARIY
				YGSSYEDWFAYWGQGLVTVSA

FIG. 12D

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M18 VL (has the same sequence as M10 VL)	SEQ ID NO: 1 QDVGTA	SEQ ID NO: 2 WAS	SEQ ID NO: 3 HQHSSNPLT	SEQ ID NO: 7 DIVMTQSHKFMSTSVGDRVSIITCKA SQDVGTAVAWYQQKPGQSPKLLIYW ASTRHIGVPDRFTGSGGTDFTLT TNVQSEDLAVYFCHQHSSNPLTFGA GTKLELK
M18 VH (has the same sequence as M10 VH)	SEQ ID NO: 4 GTFESNYA	SEQ ID NO: 5 ISNRGSYT	SEQ ID NO: 6 ARERPMDY	SEQ ID NO: 8 EVQLVESGGALVKGPGSLKLSCAAS GFTFSNYAMSWVRQPEKRLIEWAT ISNRGSYTYYPDSVKGRFTISRDN KNTLYLQMSSLRSEDTALYYCARER PMDYWGQGTSVTVSS

FIG. 12E

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M12 VL (has the same sequence as M4 VL)	SEQ ID NO: 9 KSLHNSGITY	SEQ ID NO: 10 RMS	SEQ ID NO: 11 AQMLERPWT	SEQ ID NO: 15 DIVMTQAAFSNPVTLTGTSASISCSS SKSLHNSGITYLYWYLQRPQSPQ LLIYRMSNLASGVPDFRSCSGSCTD FTLRISRVEAEDGVYYCAQMLERP WTFGGGTKLEIK
M12 VH (has the same sequence as M4 VL)	SEQ ID NO: 12 GYSFTDYL	SEQ ID NO: 13 INPYNGDA	SEQ ID NO: 14 ARLENDYGFTY	SEQ ID NO: 16 EVQLQQSGPELVKPGASVKMSCKAS GYSFTDYLNNWVKQSHGKSLEWIGR INPYNGDAFYNQRFKQKATLTVDKS SSTAHMELRSLTSEDSALYYCARLE NDYGFTYWGQGTLVTVSA

IMGT numbering system was used to identify the CDR's (ref. Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003)).

FIG. 12F

FIG. 13

Factor Bb

1 **mgsnlspqlc lmpfilglls ggvtt**tpwsl arpqqscsle gveikggsfr llqegqaley
61 vcpsgfypyp vqtrtcrstg swstlktqdq ktrkaecra ihcprphdfe ngeywprspy
121 ynvdsdeisfh cydgytlrgs anrtcqvngr wsgqtaicdn gagycsnpgi pigtrkvgsq
181 yrledsvtyh csrgltlrgs qrtrcqeggs wsgtepscqd sfmydtpgev aeafllsste
241 tiegvdaedg hgpgeqqrk ivldpsgsmn iylvldgsds igasnftgak kclvnliekv
301 asygvkpryg lvtatypki wkvseadss nadwtkqln einyedhklk sgtntkkalq
361 avysmmswpd dvppegwnrt rhviilmtdg lhnmgdpit videirdlly igkdrknpre
421 dyldvyvfgv gplvnqvnin alaskkdneg hvfkvdmen ledvfymid esqslslcgm
481 vwehrkgt dy hkqpwqakis virpskghes cmgavvseyf vltaaahcftv ddkehsikvs
541 vggekrdlei evvlfhpny ingkkaegip efydydvali klknklkygq tirpiclpct
601 egttralrlp ptttcqqqke ellpaqdika lfvsееekkl trkevyyikng dkkgsccerda
661 qyapgydkvk disevvtprf lctggvspya dpntorgdsg gpilvhkrsr fiqvgviswg
721 vvdvcknqkr qkqvpahard fhinlfqvlp wlkeklqded lgfl





FIG. 14

FIG. 15






FIG. 16

FIG. 17




FIG. 18




FIG. 19




FIG. 20





FIG. 21







FIG. 23

+M4
antibody

No CD55 added



+M4
antibody

CD55 added

